NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on March 29, 2002 and is headquartered in Pittsburgh, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. NeuBase Therapeutics Inc market cap is $1.42M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. NeuBase Therapeutics Inc 52 week high is $0.45 as of November 17, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. NeuBase Therapeutics Inc 52 week low is $0.36 as of November 17, 2026.
NeuBase Therapeutics Inc stock price today is $0.378.
NeuBase Therapeutics Inc stock price yesterday was $0.3905.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. NeuBase Therapeutics Inc 50-day moving average is $0.378.